6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

S-8 - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

6-K - Nanobiotix S.A. (0001760854) (Filer)

PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: Jefferies Global Healthcare ConferenceDate: Thursday, June 5, 2025Time: 3:45 pm EDT / 9:45 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the events page of the Investors sect

Dosing of a first patient in the CONVERGE study, a Phase 2 randomized controlled clinical trial for patients with stage 3 unresectable non-small cell lung cancerPresentation of data at the European Lung Cancer Conference in a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) in locoregional recurrent NSCLC and a Phase 1 study of JNJ-1900 (NBTXR3) in combination with nivolumab or pembrolizumab for patients with lung metastases from NSCLC or other solid tumorsStrengthened financial position through an amendment to the global licensing agreement for JNJ-1900 (NBTXR3) which extended cash runway into mid-2026 and permanently reduced operational cash burn€39.8 million in cash and cash equival

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference: H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ Date: Tuesday, May 20, 2025Time: 5:00 pm EDT / 11:00 pm CESTLocation: New York, NYPresenters: Bart van Rhijn, Chief Financial & Business Officer of NanobiotixWebcast link: Click here The fireside chats will be webcast live from the eve

Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerDisciplined financial strategy toward long-term sustainability and growth continues to strengthen financial position through focused allocation of capital, the receipt of a planned milestone payment, the transfer of sponsorship for NANORAY-312, and an amendment to the global licensing agreement for JNJ-1900 (NBTXR3)Curadigm, a next generation nanotherapeutic platform designed to reshape drug design and development across multiple therapeutic classes and disease areas, has launchedCash r

PARIS and CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, on Wednesday, April 2, 2025, after the close of the U.S. market. This release will be followed by a conference call and webcast on Thursday, April 3, 2025, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive officer, a

Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 months) and 12-month OS of 83% (median 30.2 months)The dose escalation part is complete, and 5/12 patients have been injected to date in the ongoing expansion part PARIS and CAMBRIDGE, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive, nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients,

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients with unresectable, locoregional recurrent NSCLC to be presented by principal investigator Dr. Saumil Gandhi at 8:00 AM EDT / 1:00 PM CET on Friday March 28th, 2025Data evaluating safety and injection feasibility from a Phase 1 study of JNJ-1900 (NBTXR3) in combination nivolumab or pembrolizumab for the treatment of patients with lung metastases from NSCLC or other solid tumors to be presented by principal investigator Dr. Colette Shen at 8:00 AM EDT / 1:00 PM CET on Friday March 28th, 2025 PARIS and

PARIS and CAMBRIDGE, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the execution of another disciplined step in its financial strategy through the amendment of the Company's global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company. The amendment removes Nanobiotix's funding obligation for NANORAY-312 and releases Johnson & Johnson from select future potential milestone payments, while safeguarding Nanobiotix's path to sustainable cashf

Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00